From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials

From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials

Bibliographic Details
Main Authors:	Ming-Lun Yeh, Ming-Lung Yu
Format:	Article
Language:	English
Published:	Korean Association for the Study of the Liver 2023-10-01
Series:	Clinical and Molecular Hepatology
Subjects:	nafld mafld sld masld steatosis
Online Access:	http://e-cmh.org/upload/pdf/cmh-2023-0359.pdf

Similar Items

A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease
by: Javier Martínez-Sanz, et al.
Published: (2023-12-01)

Cross talk between the liver microbiome and epigenome in patients with metabolic dysfunction-associated steatotic liver diseaseResearch in context
by: Carlos Jose Pirola, et al.
Published: (2024-03-01)

Intrapancreatic fat deposition is unrelated to liver steatosis in metabolic dysfunction-associated steatotic liver disease
by: Anne Linde Mak, et al.
Published: (2024-03-01)

Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
by: Katharina Staufer, et al.
Published: (2023-07-01)

The Effects of Butyrate on Induced Metabolic-Associated Fatty Liver Disease in Precision-Cut Liver Slices
by: Grietje H. Prins, et al.
Published: (2021-11-01)

Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease
by: Kevan Josloff, et al.
Published: (2022-11-01)

Associating Appendicitis with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Novel Insight into an Unexpected Connection
by: Christoph Roderburg, et al.
Published: (2024-02-01)

Severity and Remission of Metabolic Dysfunction–Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence
by: Jingli Gao, et al.
Published: (2024-03-01)

Nonalcoholic steatohepatitis: A comprehensive updated review of risk factors, symptoms, and treatment
by: Feryal Savari, et al.
Published: (2024-04-01)

Glucagon-like Peptide-1 Receptor Agonists—A Potential New Medication for Pediatric Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: Erika Choi, et al.
Published: (2024-02-01)

Overview of Cellular and Soluble Mediators in Systemic Inflammation Associated with Non-Alcoholic Fatty Liver Disease
by: Patrice Marques, et al.
Published: (2023-01-01)

A data-driven approach to decode metabolic dysfunction-associated steatotic liver disease
by: Maria Jimenez Ramos, et al.
Published: (2024-03-01)

Gene Variants Implicated in Steatotic Liver Disease: Opportunities for Diagnostics and Therapeutics
by: Gary Huang, et al.
Published: (2023-10-01)

Magnetic resonance‐based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
by: Cyrielle Caussy, et al.
Published: (2020-10-01)

Steatotic Liver Disease and Sepsis Outcomes—A Prospective Cohort Study (SepsisFAT)
by: Juraj Krznaric, et al.
Published: (2024-01-01)

Nonalcoholic Fatty Liver Disease, Liver Fibrosis and Cardiovascular Disease in the Adult US Population
by: Stefano Ciardullo, et al.
Published: (2021-07-01)

Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut–Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy
by: Francesca Fianchi, et al.
Published: (2021-06-01)

Nonalcoholic fatty liver disease (NAFLD) among older adults
by: Panyavee Pitisuttithum, et al.
Published: (2022-12-01)

Loss of PPARα function promotes epigenetic dysregulation of lipid homeostasis driving ferroptosis and pyroptosis lipotoxicity in metabolic dysfunction associated Steatotic liver disease (MASLD)
by: Claudia Theys, et al.
Published: (2024-01-01)

Time for micro-RNAs in steatotic liver disease: a case–control study
by: Victor Constantin Stoica, et al.
Published: (2024-03-01)

Iron, Oxidative Stress, and Metabolic Dysfunction—Associated Steatotic Liver Disease
by: Sophie Gensluckner, et al.
Published: (2024-02-01)

Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease
by: Georg Semmler, et al.
Published: (2023-09-01)

The role of intestinal disbiosis in the development of mitochondrial dysfunction and nonalcoholic fatty liver disease
by: P. V. Seliverstov, et al.
Published: (2018-04-01)

Nonalcoholic Fatty Liver Disease (NAFLD): Pathogenesis and Noninvasive Diagnosis
by: Vicneswarry Dorairaj, et al.
Published: (2021-12-01)

Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update
by: Ilaria Barchetta, et al.
Published: (2020-10-01)

Saturated Fat-Mediated Upregulation of IL-32 and CCL20 in Hepatocytes Contributes to Higher Expression of These Fibrosis-Driving Molecules in MASLD
by: Katharina Schilcher, et al.
Published: (2023-08-01)

Metabolic Dysfunction-Associated Steatotic Liver Disease in a Dish: Human Precision-Cut Liver Slices as a Platform for Drug Screening and Interventions
by: Mei Li, et al.
Published: (2024-02-01)

From Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)—New Terminology in Pediatric Patients as a Step in Good Scientific Direction?
by: Marta Flisiak-Jackiewicz, et al.
Published: (2021-03-01)

A Noninvasive Scoring System for Liver Fibrosis in Patients With Metabolic Dysfunction-Associated Fatty Liver Disease
by: Moniyka Sachar, et al.
Published: (2022-01-01)

Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?
by: Kamila Kasprzak-Drozd, et al.
Published: (2024-03-01)

The gene expression signature of metabolic dysfunction- associated steatotic liver disease from a multiomics perspective
by: Carlos Jose Pirola, et al.
Published: (2024-04-01)

Aerobic and Muscle-Strengthening Physical Activity, Television Viewing, and Nonalcoholic Fatty Liver Disease: The CARDIA Study
by: Daniel J. McDonough, et al.
Published: (2023-08-01)

Incident cardiac arrhythmias associated with metabolic dysfunction-associated steatotic liver disease: a nationwide histology cohort study
by: Tracey G. Simon, et al.
Published: (2023-12-01)

Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Screening, Diagnosis, and Treatment
by: Stefano Ciardullo, et al.
Published: (2023-08-01)

Allopurinol versus Febuxostat: A New Approach for the Management of Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Amani Al-Shargi, et al.
Published: (2023-11-01)

Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter for the Diagnosis of Liver Steatosis and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
by: Sebastian Zenovia, et al.
Published: (2021-04-01)

Lipid Metabolism in Metabolic-Associated Steatotic Liver Disease (MASLD)
by: Majid Mufaqam Syed-Abdul
Published: (2023-12-01)

Metabolic Fatty Liver Disease in Children: A Growing Public Health Problem
by: Sébastien Le Garf, et al.
Published: (2021-12-01)

MAFLD: How is it different from NAFLD?
by: Cameron Gofton, et al.
Published: (2023-02-01)

Noninvasive assessment of nonalcoholic fatty liver disease
by: Gajanan A Rodge, et al.
Published: (2021-01-01)